Response to letter on : The methodological considerations of the inhaled Aviptadil trial for COVID-19 related lung damage.

Zyesami inhalation (aviptadil) - Relief Therap, United Therapeutics Corp, Seren Clinical, NRx Pharma

http://www.ncbi.nlm.nih.gov/pubmed/40652932

Dorina Esendagli

Jul 14, 2025